Tumor profiling: Shifting from DNA to RNA sequencing
March 2, 2020
Personalized biopsy-driven treatment based on DNA sequencing has been tested in various settings for over ten years. Unfortunately, the response rate is disappointing. A recent study shows that profiling RNA, instead of DNA, allows the more advanced cancer patients to benefit from personalized therapies, compared to the standard analysis of DNA alterations alone.